Treatment Review; August 1995
Crixivan is also being studied in a clinical trial. Like the
expanded access program, less than 50 T4 cells are required
to participate in this program. The trial will study 3
different drugs in combination and alone for the treatment of
HIV infection. The drugs are Crixivan (MK-639), AZT and 3TC.
You must have taken and tolerated AZT for more than 6 months
at the standard dose to be eligible to participate.
Participants will be divided into three groups. The first
group will take AZT and 3TC. The second group will take the
protease inhibitor. The third group will take all three study
There is also a special, open label arm of this study for
people who can't take AZT, have used AZT for less than six
months, or have taken 3TC before.